Aligos Therapeutics, Inc. generated $2.2M in revenue in fiscal year 2025. This represents a decrease of 39.5% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $3.7M in revenue. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Aligos Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ALGS Revenue by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
ALGS Revenue by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What revenue means
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.
More Aligos Therapeutics, Inc. financials
Frequently Asked Questions
What was Aligos Therapeutics, Inc.'s revenue in fiscal year 2025?
Aligos Therapeutics, Inc. generated $2.2M in revenue in fiscal year 2025.
How fast is Aligos Therapeutics, Inc.'s revenue growing?
Aligos Therapeutics, Inc. (ALGS) revenue fell by 39.5% year over year, from $3.6M to $2.2M in fiscal year 2025.
What is Aligos Therapeutics, Inc.'s revenue over the last twelve months?
Aligos Therapeutics, Inc. (ALGS) reported $3.7M in revenue over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Aligos Therapeutics, Inc.'s revenue in the most recent quarter?
Aligos Therapeutics, Inc. (ALGS) reported $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
What does revenue mean on a financial statement?
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Aligos Therapeutics, Inc. (ALGS) reported on that line in every period on record.